Τίτλος:
16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Antiphospholipid syndrome (APS), an acquired autoimmune thrombophilia, is characterised by thrombosis and/or pregnancy morbidity in association with persistent antiphospholipid antibodies. The 16th International Congress on Antiphospholipid Antibodies Task Force on APS Treatment Trends reviewed the current status with regard to existing and novel treatment trends for APS, which is the focus of this Task Force report. The report addresses current treatments and developments since the last report, on the use of direct oral anticoagulants in patients with APS, antiplatelet agents, adjunctive therapies (hydroxychloroquine, statins and vitamin D), targeted treatment including rituximab, belimumab, and anti-TNF agents, complement inhibition and drugs based on peptides of beta-2-glycoprotein I. In addition, the report summarises potential new players, including coenzyme Q10, adenosine receptor agonists and adenosine potentiation. In each case, the report provides recommendations for clinicians, based on the current state of the art, and suggests a clinical research agenda. The initiation and development of appropriate clinical studies requires a focus on devising suitable outcome measures, including a disease activity index, an optimal damage index, and a specific quality of life index. © The Author(s) 2020.
Συγγραφείς:
Cohen, H.
Cuadrado, M.J.
Erkan, D.
Duarte-Garcia, A.
Isenberg, D.A.
Knight, J.S.
Ortel, T.L.
Rahman, A.
Salmon, J.E.
Tektonidou, M.G.
Williams, D.J.
Willis, R.
Woller, S.C.
Andrade, D.
Περιοδικό:
Lupus Science and Medicine
Εκδότης:
SAGE Publications Ltd
Λέξεις-κλειδιά:
acetylsalicylic acid; adenosine; adenosine receptor stimulating agent; anticoagulant agent; antivitamin K; apixaban; belimumab; beta2 glycoprotein 1; complement inhibitor; hydroxychloroquine; hydroxymethylglutaryl coenzyme A reductase inhibitor; new drug; phospholipid antibody; rituximab; rivaroxaban; tumor necrosis factor inhibitor; ubidecarenone; vitamin D; blood clotting factor 10a; phospholipid antibody, anticoagulant therapy; antiphospholipid syndrome; Article; biological therapy; cerebrovascular accident; clinical research; clinician; comparative effectiveness; complement inhibition; domain i; domain v; drug use; equivalence trial (topic); evidence based practice; human; low drug dose; meta analysis (topic); pathogenesis; phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 4 clinical trial (topic); practice guideline; pregnancy; primary prevention; priority journal; protein structure; randomized controlled trial (topic); secondary prevention; systematic review (topic); therapy; thrombosis; thrombosis prevention; trend study; venous thromboembolism; vitamin D deficiency; antiphospholipid syndrome; complication; immunology; organization; thrombosis, Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Congresses as Topic; Factor Xa; Humans; Hydroxychloroquine; Thrombosis
DOI:
10.1177/0961203320950461
